Brain Advance Access originally published online on April 23, 2007
Brain 2007 130(7):1819-1833; doi:10.1093/brain/awm082
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
1Neurobiology Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden and 2CNS Disease Modeling Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, Lund, Sweden
Correspondence to: Manolo Carta, PhD, Wallenberg Neuroscience Center, BMC-A11, 22184 Lund, Sweden E-mail: manolo.carta{at}med.lu.se
In patients with Parkinson's disease, the therapeutic efficacy of L-DOPA medication is gradually lost over time, and abnormal involuntary movements, dyskinesias, gradually emerge as a prominent side-effect in response to previously beneficial doses of the drug. Here we show that dyskinesia induced by chronic L-DOPA treatment in rats with 6-hydroxydopamine-induced lesions of the nigrostriatal dopamine pathway is critically dependent on the integrity and function of the serotonergic system. Removal of the serotonin afferents, or dampening of serotonin neuron activity by 5-HT1A and 5-HT1B agonist drugs, resulted in a near-complete block of the L-DOPA-induced dyskinesias, suggesting that dysregulated dopamine release from serotonin terminals is the prime trigger of dyskinesia in the rat Parkinson's disease model. In animals with complete dopamine lesions, the spared serotonin innervation was unable to sustain the therapeutic effect of L-DOPA, suggesting that dopamine released as a ‘false transmitter’ from serotonin terminals is detrimental rather than beneficial. The potent synergistic effect of low doses of 5-HT1A and 5-HT1B agonists to suppress dyskinesia, without affecting the anti-parkinsonian effect of L-DOPA in presence of spared dopamine terminals, suggests an early use of these drugs to counteract the development of dyskinesia in Parkinson's disease patients.
Key Words: Parkinson's disease; dyskinesia; serotonin; dopamine; 5-HT1A/1B agonists
Abbreviations: AIM, abnormal involuntary movement; DA, dopamine; MFB, medial forebrain bundle; PD, Parkinson's disease
Received December 5, 2006. Revised January 31, 2007. Accepted March 16, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Bjorklund, T. Carlsson, E. A. Cederfjall, M. Carta, and D. Kirik Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease Brain, February 2, 2010; (2010): awp314v1 - awp314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bjorklund, T. Bjorklund, and D. Kirik Gene Therapy for Dopamine Replacement in Parkinsons Disease Science Translational Medicine, October 14, 2009; 1(2): 2ps2 - 2ps2. [Full Text] [PDF]
|
|
|
|
|
|
T. Carlsson, M. Carta, A. Munoz, B. Mattsson, C. Winkler, D. Kirik, and A. Bjorklund Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration Brain, February 1, 2009; 132(2): 319 - 335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Visanji, S. H. Fox, T. H. Johnston, M. J. Millan, and J. M. Brotchie {alpha}1-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 276 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, December 1, 2008; 131(12): 3380 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, W.-M. Zhu, D. Stanic, D. I. Finkelstein, M. H. Horne, J. Henderson, A. J. Lawrence, L. O'Connor, D. Tomas, J. Drago, et al. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia Brain, June 1, 2008; 131(6): 1574 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hirano, K. Asanuma, Y. Ma, C. Tang, A. Feigin, V. Dhawan, M. Carbon, and D. Eidelberg Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease J. Neurosci., April 16, 2008; 28(16): 4201 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hashimoto and H. Kita Serotonin Activates Presynaptic and Postsynaptic Receptors in Rat Globus Pallidus J Neurophysiol, April 1, 2008; 99(4): 1723 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, P. E. Andren, P. Greengard, and P. Svenningsson Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism PNAS, February 12, 2008; 105(6): 2163 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kish, J. Tong, O. Hornykiewicz, A. Rajput, L.-J. Chang, M. Guttman, and Y. Furukawa Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease Brain, January 1, 2008; 131(1): 120 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Carlsson, M. Carta, C. Winkler, A. Bjorklund, and D. Kirik Serotonin Neuron Transplants Exacerbate L-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease J. Neurosci., July 25, 2007; 27(30): 8011 - 8022. [Abstract] [Full Text] [PDF]
|
|